I attended SABCS in San Antonio and spent time reviewing Milana Dolezal, M.D., M.Sci poster, which I found particularly interesting in the context of how the field continues to think about immune architecture and the tumour microenvironment in metastatic breast cancer.
One aspect that stood out was the durability observed in a small cohort of patients, where five individuals were alive at a median of ~60 months following their last line of therapy — which included a CCR5 antagonist in combination with immune checkpoint inhibition and chemotherapy.
When viewed alongside related CCR5-focused data presented earlier this year at ESMO in Munich, as well as findings discussed at ESMO GI in Barcelona, it reinforces a broader evolution in the science: moving beyond single-pathway thinking toward a more integrated view of immune modulation, metastatic biology, and clinical translation across disease settings.
I’ve included links to the SABCS poster, along with the related ESMO Munich and ESMO GI posters, for those interested in following how this narrative continues to take shape.
hashtag#ImmunoOncology
hashtag#TumorMicroenvironment
hashtag#TranslationalMedicine
hashtag#CancerResearch
hashtag#BreastCancer
hashtag#ColorectalCancer
hashtag#MetastaticCancer
hashtag#ImmuneModulation
hashtag#HostDirectedTherapy
hashtag#InfectiousDiseaseResearch
hashtag#PrecisionMedicine
hashtag#BiotechLeadership
hashtag#GlobalHealth
hashtag#PatientCentricCare
hashtag#Biodefense
https://lnkd.in/eWxsBgAv
https://lnkd.in/eCVJn9fM
https://lnkd.in/evdSxvgh
Leronlimab_TNBC_SABCS_2025_FINAL.pdf
d1io3yog0oux5.cloudfront.net